Status:
RECRUITING
Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies
Lead Sponsor:
Duke University
Collaborating Sponsors:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Conditions:
Hematologic Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen recepto...
Detailed Description
The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of MDSCs over time in patients receiving CAR T therapy and determine the correlation between immune ...
Eligibility Criteria
Inclusion
- Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
- Has a confirmed diagnosis of hematologic malignancy and will be undergoing CAR T therapy with commercial CAR T product.
- Patient who has a confirmed diagnosis of hematologic malignancy and will be receiving CAR T therapy under clinical trial protocol will also be eligible if the clinical trial sponsor and the investigator approve patient participation in the study.
Exclusion
- NA
Key Trial Info
Start Date :
May 27 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05397132
Start Date
May 27 2022
End Date
November 1 2026
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University
Durham, North Carolina, United States, 27710